SCHEMBL140313

SCHEMBL140313

CCOc1ccc2nc(Nc3cc(C(F)(F)c4ccc(F)cc4)nc(Cl)n3)sc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 3/20 0.55
▸ ITK Q08881 3/20 0.55
▸ AURKB Q96GD4 1/20 0.55
▸ KMT2A Q03164 4/20 0.46
▸ MAPT P10636 8/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ HPGD P15428 3/20 0.46
▸ TDP1 Q9NUW8 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ SMN1; SMN2 Q16637 6/20 0.45
▸ HSD17B10 Q99714 3/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ HTT P42858 2/20 0.45
▸ TP53 P04637 3/20 0.44
▸ CSNK1D P48730 3/20 0.44
▸ NPC1 O15118 5/20 0.43
▸ RAB9A P51151 5/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL141486 0.90 LCK (0.67) LCKITKAURKBKMT2AMAPT
SCHEMBL138176 0.88 LCK (0.55) LCKITKAURKBKMT2AMAPT
SCHEMBL143889 0.83 LCK (0.49) LCKITKAURKBKMT2AMAPT
SCHEMBL138887 0.81 RAB9A (0.52) LCKITKAURKBKMT2AMAPT
SCHEMBL144162 0.81 LCK (0.84) LCKITKAURKBKMT2AMAPT
SCHEMBL144163 0.81 LCK (0.84) LCKITKAURKBKMT2AMAPT
SCHEMBL141146 0.78 MAPT (0.53) LCKITKAURKBKMT2AMAPT
SCHEMBL136247 0.77 LCK (0.67) LCKITKAURKBKMT2AMAPT
SCHEMBL144539 0.76 MAPT (0.55) LCKITKAURKBKMT2AMAPT
SCHEMBL142375 0.75 LCK (0.69) LCKITKAURKBKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 — — US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 — — US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 — — EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK LCK 189/4885ITK 2/4885AURKB 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback